SIGA - SIGA Technologies, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.58
-0.06 (-1.06%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.64
Open5.58
Bid5.00 x 3200
Ask5.74 x 2200
Day's Range5.40 - 5.74
52 Week Range3.90 - 8.47
Volume208,789
Avg. Volume194,775
Market Cap448.246M
Beta (3Y Monthly)2.46
PE Ratio (TTM)N/A
EPS (TTM)-0.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • How Immersion Corporation (IMMR) Stacks Up Against Its Market Cap Peers
    Insider Monkey11 days ago

    How Immersion Corporation (IMMR) Stacks Up Against Its Market Cap Peers

    Is Immersion Corporation (NASDAQ:IMMR) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy league graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of […]

  • GlobeNewswire16 days ago

    SIGA Announces Priority Review Voucher Transaction Totaling $80 Million

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into an agreement to sell its medical countermeasures priority review voucher (PRV) for a lump sum payment of $80 million. SIGA was awarded the PRV in July 2018 upon approval by the U.S. Food and Drug Administration (FDA) of oral TPOXX® for the treatment of smallpox. The PRV was awarded by FDA under a provision that encourages development of medical countermeasures enacted as part of the 21st Century Cures Act (Public Law 114-255).

  • GlobeNewswirelast month

    SIGA Enters into Cooperative Research and Development Agreement with U.S. Army Medical Research Institute of Infectious Disease to Evaluate the Efficacy of TPOXX® as a Post-Exposure Prophylactic for Smallpox

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).  This CRADA will focus on Good Laboratory Practice (GLP) studies of TPOXX® for post-exposure prophylaxis (PEP) using a U.S. Food and Drug Administration (FDA)-approved non-human primate model of TPOXX efficacy against smallpox infection. PEP regimens are designed to prevent infection in individuals who have known or potential exposure to an infectious agent but are not symptomatic.

  • GlobeNewswire2 months ago

    SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Phillip L. Gomez, SIGA’s Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference in New York City at 8:35 am ET on Tuesday, October 2, 2018. To access the live webcast, please visit the Investor Relations section of the Company's website, under Events & Presentations. As previously announced, SIGA will host a business update webcast and conference call today at 4:30 P.M. ET.  The live webcast will be available in the Investor Relations section of the company’s website.  Participants may also call (877) 407-6184 (United States/Canada) or (201) 389-0877 (International) and request the SIGA Technologies call or provide confirmation code 13683284.

  • GlobeNewswire2 months ago

    SIGA Technologies to Host Business Update Webcast on September 27, 2018

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, September 27, 2018. A live webcast will be available on the Company's website, www.SIGA.com, under the 'Events & Presentations' tab in the Investor Relations section. Participants may also call (877) 407-6184 (United States/Canada) or (201) 389-0877 (International) and request the SIGA Technologies call or provide confirmation code 13683284.

  • GlobeNewswire2 months ago

    SIGA Technologies to Ring the Nasdaq Opening Bell on Friday, September 14, 2018

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that that management will be ringing the Nasdaq Stock Market Opening Bell on Friday, September 14, 2018. “To date 2018 has been a historic year for SIGA and we are pleased to have the opportunity to recognize our multiple achievements as we ring the Nasdaq opening bell,” said Phil Gomez, CEO of SIGA Technologies. SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market.

  • GlobeNewswire2 months ago

    SIGA Technologies Awarded BARDA Contract for TPOXX®

    SIGA Technologies, Inc. (SIGA) (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the delivery of oral and intravenous (IV) formulations of TPOXX® to the Strategic National Stockpile. The contract also covers advanced development of the IV formulation and post-marketing activities for the oral formulation of TPOXX. The contract (HHSO100201800019C) is valued at up to $629 million, and consists of a five-year base period of performance and a total contract period of performance (base period plus option exercises) of up to ten years (if necessary).

  • Benzinga4 months ago

    Siga Continues Rally After FDA Approves Smallpox Drug

    Siga Technologies (NASDAQ: SIGA) announced the FDA's approval of TPOXX, or tecovirimat. The drug consists of an antiviral treatment designed to diminish the effects of smallpox upon outbreak and is the first approved treatment of its kind. The smallpox drug's importance is twofold.

  • Benzinga7 months ago

    Benzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks ( Stocks hitting 52-week highs on May 2 ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Eleven Biotherapeutics ...

  • Benzinga7 months ago

    Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 1) ABIOMED, Inc. (NASDAQ: ABMD ) AveXis Inc (NASDAQ: AVXS ) (announced ...

  • ACCESSWIRE9 months ago

    Emerging Developments: New Research on Siga Technologies and Tropicana Entertainment - A Look Ahead into 2018

    NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Siga Technologies Inc. (OTC PINK: SIGA) and Tropicana Entertainment ...